Skip to main content

Table 3 Main modeling outcomes

From: Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach

Treatment naïves population
  PR Boceprevir + PR SOF/RBV SOF/SMV
Clinical outcomes
 SVR (24 weeks after tx) 46.62 % 58.58 % 47.37 % 93.31 %
 Decompensated cirrhosis 11.88 % 10.07 % 10.64 % 1.73 %
 Hepatocellular carcinoma 5.65 % 4.97 % 5.30 % 2.15 %
 Liver Transplantation 1.42 % 1.22 % 1.27 % 0.26 %
 Liver related death 13.52 % 11.71 % 12.22 % 3.22 %
Costs
 Total Costs 35,358.93 € 52,679.70 € 127,891.69 € 106,868.76 €
 Drug costs 21,842.68 € 41,842.96 € 117,578.96 € 103,641.74 €
 Of which PI - € 23,606.10 € 113,152.56 € 102,535.14 €
 Of which (P)R 21,842.68 € 18,236.86 € 4,426.40 € 1,106.60 €
 Pre-treatment evaluation 170.99 € 85.00 € 85.00 € 85.00 €
 Monitoring costs 1,287.97 € 1,207.16 € 1,084.00 € 878.97 €
 Adverse event cost 450.07 € 923.49 € 7.00 € 162.53 €
 SVR, F0-F2 50.75 € 66.06 € 46.86 € 94.11 €
 SVR, F3 25.34 € 13.18 € 15.16 € 28.64 €
 SVR, F4 63.40 € 27.77 € 31.94 € 60.34 €
 F0-F2 703.42 € 491.51 € 778.50 € 72.15 €
 F3 2,881.21 € 1,109.77 € 1,268.17 € 185.75 €
 F4 1,258.16 € 1,082.28 € 1,105.84 € 187.26 €
 DCC 2,963.85 € 2,595.90 € 2,614.33 € 450.92 €
 HCC 1,459.78 € 1,307.52 € 1,348.52 € 588.77 €
 LT 1,133.50 € 987.14 € 998.37 € 219.54 €
 pLT 1,067.81 € 939.97 € 929.03 € 213.03 €
  1. PR PegInterferon and Ribavirin, SOF Sofosbuvir, SMV Simeprevir, SVR sustained virologic response, PI protease inhibitor, fibrosis states F0-F4 according to METAVIR, DCC decompensated cirrhosis, HCC hepatocellular carcinoma, LT, first year after liver transplant, pLT further years after liver transplant